nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—skin cancer—psoriasis	0.481	1	CtDrD
Vismodegib—SMO—Fluocinonide—psoriasis	0.305	0.729	CbGbCtD
Vismodegib—ALB—Acitretin—psoriasis	0.00973	0.0233	CbGbCtD
Vismodegib—CYP2C8—Tazarotene—psoriasis	0.00951	0.0228	CbGbCtD
Vismodegib—SHH—vertebral column—psoriasis	0.00852	0.427	CbGeAlD
Vismodegib—ABCG2—Mycophenolate mofetil—psoriasis	0.00661	0.0158	CbGbCtD
Vismodegib—ABCG2—Hydrocortisone—psoriasis	0.0053	0.0127	CbGbCtD
Vismodegib—SHH—skin epidermis—psoriasis	0.00522	0.262	CbGeAlD
Vismodegib—ABCG2—Cyclosporine—psoriasis	0.00501	0.012	CbGbCtD
Vismodegib—ALB—Mycophenolate mofetil—psoriasis	0.00456	0.0109	CbGbCtD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—KRT10—psoriasis	0.00407	0.14	CbGpPWpGaD
Vismodegib—CYP2C8—Cholecalciferol—psoriasis	0.00406	0.00971	CbGbCtD
Vismodegib—ALB—Prednisone—psoriasis	0.00364	0.00871	CbGbCtD
Vismodegib—CYP2C8—Mycophenolate mofetil—psoriasis	0.00352	0.00842	CbGbCtD
Vismodegib—CYP2C19—Cholecalciferol—psoriasis	0.00341	0.00815	CbGbCtD
Vismodegib—ABCG2—Dexamethasone—psoriasis	0.0033	0.00789	CbGbCtD
Vismodegib—CYP3A4—Calcitriol—psoriasis	0.0032	0.00765	CbGbCtD
Vismodegib—CYP2C9—Cholecalciferol—psoriasis	0.00283	0.00677	CbGbCtD
Vismodegib—CYP2C8—Hydrocortisone—psoriasis	0.00283	0.00676	CbGbCtD
Vismodegib—CYP2C8—Cyclosporine—psoriasis	0.00267	0.00638	CbGbCtD
Vismodegib—ABCG2—Methotrexate—psoriasis	0.00265	0.00634	CbGbCtD
Vismodegib—ORM1—vertebral column—psoriasis	0.0026	0.13	CbGeAlD
Vismodegib—CYP3A4—Methoxsalen—psoriasis	0.00249	0.00595	CbGbCtD
Vismodegib—ABCB1—Mycophenolate mofetil—psoriasis	0.00238	0.0057	CbGbCtD
Vismodegib—CYP2C19—Prednisone—psoriasis	0.00236	0.00565	CbGbCtD
Vismodegib—CYP2C19—Cyclosporine—psoriasis	0.00224	0.00535	CbGbCtD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—IVL—psoriasis	0.0021	0.0721	CbGpPWpGaD
Vismodegib—ABCB1—Betamethasone—psoriasis	0.00204	0.00489	CbGbCtD
Vismodegib—ABCB1—Prednisolone—psoriasis	0.00202	0.00483	CbGbCtD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—IVL—psoriasis	0.00199	0.0684	CbGpPWpGaD
Vismodegib—ABCB1—Hydrocortisone—psoriasis	0.00191	0.00457	CbGbCtD
Vismodegib—ABCB1—Prednisone—psoriasis	0.00191	0.00456	CbGbCtD
Vismodegib—CYP2C9—Cyclosporine—psoriasis	0.00186	0.00445	CbGbCtD
Vismodegib—ALB—Methotrexate—psoriasis	0.00183	0.00437	CbGbCtD
Vismodegib—ABCB1—Cyclosporine—psoriasis	0.00181	0.00432	CbGbCtD
Vismodegib—CYP2C8—Dexamethasone—psoriasis	0.00176	0.0042	CbGbCtD
Vismodegib—CYP3A4—Cholecalciferol—psoriasis	0.00165	0.00394	CbGbCtD
Vismodegib—SHH—skin of body—psoriasis	0.00162	0.0811	CbGeAlD
Vismodegib—CYP2C19—Dexamethasone—psoriasis	0.00147	0.00353	CbGbCtD
Vismodegib—CYP3A4—Triamcinolone—psoriasis	0.00143	0.00342	CbGbCtD
Vismodegib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00143	0.00342	CbGbCtD
Vismodegib—CYP2C9—Dexamethasone—psoriasis	0.00123	0.00293	CbGbCtD
Vismodegib—CYP3A4—Betamethasone—psoriasis	0.00123	0.00293	CbGbCtD
Vismodegib—CYP3A4—Prednisolone—psoriasis	0.00121	0.00289	CbGbCtD
Vismodegib—ABCB1—Dexamethasone—psoriasis	0.00119	0.00284	CbGbCtD
Vismodegib—CYP3A4—Hydrocortisone—psoriasis	0.00115	0.00274	CbGbCtD
Vismodegib—CYP3A4—Prednisone—psoriasis	0.00114	0.00273	CbGbCtD
Vismodegib—SMO—skin of body—psoriasis	0.00113	0.0567	CbGeAlD
Vismodegib—CYP3A4—Cyclosporine—psoriasis	0.00108	0.00259	CbGbCtD
Vismodegib—ABCB1—Methotrexate—psoriasis	0.000956	0.00229	CbGbCtD
Vismodegib—SMO—tendon—psoriasis	0.000862	0.0432	CbGeAlD
Vismodegib—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00077	0.0265	CbGpPWpGaD
Vismodegib—CYP3A4—Dexamethasone—psoriasis	0.000713	0.0017	CbGbCtD
Vismodegib—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000687	0.0236	CbGpPWpGaD
Vismodegib—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000626	0.0215	CbGpPWpGaD
Vismodegib—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000477	0.0164	CbGpPWpGaD
Vismodegib—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000426	0.0146	CbGpPWpGaD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—VDR—psoriasis	0.000425	0.0146	CbGpPWpGaD
Vismodegib—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000388	0.0133	CbGpPWpGaD
Vismodegib—Sulfasalazine—PPARG—psoriasis	0.000371	1	CrCbGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000337	0.0116	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL22—psoriasis	0.000333	0.0115	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.00032	0.011	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—HCAR2—psoriasis	0.000301	0.0104	CbGpPWpGaD
Vismodegib—SHH—Dopaminergic Neurogenesis—STAT3—psoriasis	0.000291	0.01	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—HCAR2—psoriasis	0.000286	0.00982	CbGpPWpGaD
Vismodegib—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000256	0.0088	CbGpPWpGaD
Vismodegib—SHH—FOXA1 transcription factor network—JUN—psoriasis	0.000248	0.00852	CbGpPWpGaD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—NFKB1—psoriasis	0.000248	0.00851	CbGpPWpGaD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—NFKB1—psoriasis	0.000235	0.00807	CbGpPWpGaD
Vismodegib—SHH—Heart Development—VEGFA—psoriasis	0.000217	0.00744	CbGpPWpGaD
Vismodegib—ABCG2—Iron uptake and transport—CP—psoriasis	0.000213	0.00733	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—VEGFA—psoriasis	0.000202	0.00694	CbGpPWpGaD
Vismodegib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000198	0.00681	CbGpPWpGaD
Vismodegib—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000195	0.00672	CbGpPWpGaD
Vismodegib—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000177	0.00608	CbGpPWpGaD
Vismodegib—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000174	0.006	CbGpPWpGaD
Vismodegib—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000161	0.00554	CbGpPWpGaD
Vismodegib—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000161	0.00552	CbGpPWpGaD
Vismodegib—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000159	0.00547	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCL20—psoriasis	0.000156	0.00538	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HCAR2—psoriasis	0.000155	0.00531	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000151	0.0052	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL20—psoriasis	0.000148	0.0051	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HCAR2—psoriasis	0.000147	0.00504	CbGpPWpGaD
Vismodegib—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000143	0.00493	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—IL6—psoriasis	0.00014	0.0048	CbGpPWpGaD
Vismodegib—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000139	0.00479	CbGpPWpGaD
Vismodegib—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000138	0.00474	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000137	0.00473	CbGpPWpGaD
Vismodegib—Pain—Acitretin—psoriasis	0.000134	0.00258	CcSEcCtD
Vismodegib—Constipation—Acitretin—psoriasis	0.000134	0.00258	CcSEcCtD
Vismodegib—Pain—Fluocinolone Acetonide—psoriasis	0.000134	0.00258	CcSEcCtD
Vismodegib—Weight decreased—Cyclosporine—psoriasis	0.000133	0.00256	CcSEcCtD
Vismodegib—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000131	0.00449	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.00013	0.00448	CbGpPWpGaD
Vismodegib—Weight decreased—Mycophenolate mofetil—psoriasis	0.00013	0.00249	CcSEcCtD
Vismodegib—Alopecia—Mycophenolic acid—psoriasis	0.000129	0.00247	CcSEcCtD
Vismodegib—Gastrointestinal pain—Acitretin—psoriasis	0.000129	0.00247	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000128	0.00246	CcSEcCtD
Vismodegib—Asthenia—Calcitriol—psoriasis	0.000127	0.00244	CcSEcCtD
Vismodegib—Malnutrition—Mycophenolic acid—psoriasis	0.000127	0.00243	CcSEcCtD
Vismodegib—Pruritus—Calcitriol—psoriasis	0.000125	0.0024	CcSEcCtD
Vismodegib—Rash—Methoxsalen—psoriasis	0.000125	0.0024	CcSEcCtD
Vismodegib—Dermatitis—Methoxsalen—psoriasis	0.000125	0.0024	CcSEcCtD
Vismodegib—Abdominal pain—Acitretin—psoriasis	0.000124	0.00239	CcSEcCtD
Vismodegib—Back pain—Mycophenolic acid—psoriasis	0.000122	0.00235	CcSEcCtD
Vismodegib—Muscle spasms—Mycophenolic acid—psoriasis	0.000122	0.00234	CcSEcCtD
Vismodegib—Nervous system disorder—Hydroxyurea—psoriasis	0.000121	0.00233	CcSEcCtD
Vismodegib—Diarrhoea—Calcitriol—psoriasis	0.000121	0.00232	CcSEcCtD
Vismodegib—Skin disorder—Hydroxyurea—psoriasis	0.00012	0.0023	CcSEcCtD
Vismodegib—Weight decreased—Hydrocortisone—psoriasis	0.000118	0.00227	CcSEcCtD
Vismodegib—Nausea—Methoxsalen—psoriasis	0.000118	0.00226	CcSEcCtD
Vismodegib—Hypokalaemia—Betamethasone—psoriasis	0.000118	0.00226	CcSEcCtD
Vismodegib—Hypokalaemia—Dexamethasone—psoriasis	0.000118	0.00226	CcSEcCtD
Vismodegib—Connective tissue disorder—Cyclosporine—psoriasis	0.000116	0.00222	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000116	0.00397	CbGpPWpGaD
Vismodegib—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000113	0.00217	CcSEcCtD
Vismodegib—Asthenia—Acitretin—psoriasis	0.000113	0.00217	CcSEcCtD
Vismodegib—Vomiting—Calcitriol—psoriasis	0.000112	0.00216	CcSEcCtD
Vismodegib—Rash—Calcitriol—psoriasis	0.000111	0.00214	CcSEcCtD
Vismodegib—Dermatitis—Calcitriol—psoriasis	0.000111	0.00214	CcSEcCtD
Vismodegib—Pruritus—Acitretin—psoriasis	0.000111	0.00214	CcSEcCtD
Vismodegib—Pruritus—Fluocinolone Acetonide—psoriasis	0.000111	0.00213	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000109	0.00376	CbGpPWpGaD
Vismodegib—Dyspepsia—Hydroxyurea—psoriasis	0.000109	0.00209	CcSEcCtD
Vismodegib—Myalgia—Mycophenolic acid—psoriasis	0.000108	0.00207	CcSEcCtD
Vismodegib—Arthralgia—Mycophenolic acid—psoriasis	0.000108	0.00207	CcSEcCtD
Vismodegib—Diarrhoea—Acitretin—psoriasis	0.000108	0.00207	CcSEcCtD
Vismodegib—Decreased appetite—Hydroxyurea—psoriasis	0.000107	0.00206	CcSEcCtD
Vismodegib—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000107	0.00206	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000107	0.00206	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000107	0.00205	CcSEcCtD
Vismodegib—Fatigue—Hydroxyurea—psoriasis	0.000106	0.00205	CcSEcCtD
Vismodegib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000106	0.00365	CbGpPWpGaD
Vismodegib—Pain—Hydroxyurea—psoriasis	0.000106	0.00203	CcSEcCtD
Vismodegib—Constipation—Hydroxyurea—psoriasis	0.000106	0.00203	CcSEcCtD
Vismodegib—Nausea—Calcitriol—psoriasis	0.000105	0.00202	CcSEcCtD
Vismodegib—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000105	0.00361	CbGpPWpGaD
Vismodegib—Alopecia—Cyclosporine—psoriasis	0.000104	0.002	CcSEcCtD
Vismodegib—Connective tissue disorder—Hydrocortisone—psoriasis	0.000103	0.00198	CcSEcCtD
Vismodegib—Malnutrition—Cyclosporine—psoriasis	0.000102	0.00197	CcSEcCtD
Vismodegib—Hypokalaemia—Prednisone—psoriasis	0.000102	0.00197	CcSEcCtD
Vismodegib—Alopecia—Mycophenolate mofetil—psoriasis	0.000101	0.00195	CcSEcCtD
Vismodegib—Nervous system disorder—Mycophenolic acid—psoriasis	0.000101	0.00195	CcSEcCtD
Vismodegib—Weight decreased—Dexamethasone—psoriasis	0.000101	0.00194	CcSEcCtD
Vismodegib—Weight decreased—Betamethasone—psoriasis	0.000101	0.00194	CcSEcCtD
Vismodegib—Skin disorder—Mycophenolic acid—psoriasis	0.0001	0.00193	CcSEcCtD
Vismodegib—Dysgeusia—Cyclosporine—psoriasis	0.0001	0.00193	CcSEcCtD
Vismodegib—Malnutrition—Mycophenolate mofetil—psoriasis	9.99e-05	0.00192	CcSEcCtD
Vismodegib—Vomiting—Acitretin—psoriasis	9.99e-05	0.00192	CcSEcCtD
Vismodegib—Vomiting—Fluocinolone Acetonide—psoriasis	9.97e-05	0.00192	CcSEcCtD
Vismodegib—Rash—Acitretin—psoriasis	9.91e-05	0.00191	CcSEcCtD
Vismodegib—Dermatitis—Acitretin—psoriasis	9.9e-05	0.0019	CcSEcCtD
Vismodegib—Rash—Fluocinolone Acetonide—psoriasis	9.88e-05	0.0019	CcSEcCtD
Vismodegib—Dermatitis—Fluocinolone Acetonide—psoriasis	9.87e-05	0.0019	CcSEcCtD
Vismodegib—Muscle spasms—Cyclosporine—psoriasis	9.85e-05	0.00189	CcSEcCtD
Vismodegib—Dysgeusia—Mycophenolate mofetil—psoriasis	9.79e-05	0.00188	CcSEcCtD
Vismodegib—Back pain—Mycophenolate mofetil—psoriasis	9.67e-05	0.00186	CcSEcCtD
Vismodegib—Muscle spasms—Mycophenolate mofetil—psoriasis	9.61e-05	0.00185	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	9.42e-05	0.00181	CcSEcCtD
Vismodegib—Nausea—Acitretin—psoriasis	9.34e-05	0.00179	CcSEcCtD
Vismodegib—Nausea—Fluocinolone Acetonide—psoriasis	9.31e-05	0.00179	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—HCAR2—psoriasis	9.13e-05	0.00314	CbGpPWpGaD
Vismodegib—Malnutrition—Hydrocortisone—psoriasis	9.1e-05	0.00175	CcSEcCtD
Vismodegib—Dyspepsia—Mycophenolic acid—psoriasis	9.1e-05	0.00175	CcSEcCtD
Vismodegib—Decreased appetite—Mycophenolic acid—psoriasis	8.98e-05	0.00173	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	8.92e-05	0.00172	CcSEcCtD
Vismodegib—Fatigue—Mycophenolic acid—psoriasis	8.91e-05	0.00171	CcSEcCtD
Vismodegib—Asthenia—Hydroxyurea—psoriasis	8.85e-05	0.0017	CcSEcCtD
Vismodegib—Constipation—Mycophenolic acid—psoriasis	8.84e-05	0.0017	CcSEcCtD
Vismodegib—Pain—Mycophenolic acid—psoriasis	8.84e-05	0.0017	CcSEcCtD
Vismodegib—Weight decreased—Prednisone—psoriasis	8.8e-05	0.00169	CcSEcCtD
Vismodegib—Myalgia—Cyclosporine—psoriasis	8.72e-05	0.00168	CcSEcCtD
Vismodegib—Arthralgia—Cyclosporine—psoriasis	8.72e-05	0.00168	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	8.66e-05	0.00167	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—HCAR2—psoriasis	8.66e-05	0.00298	CbGpPWpGaD
Vismodegib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.62e-05	0.00296	CbGpPWpGaD
Vismodegib—CYP2C8—Biological oxidations—CYP2S1—psoriasis	8.53e-05	0.00293	CbGpPWpGaD
Vismodegib—Myalgia—Mycophenolate mofetil—psoriasis	8.51e-05	0.00164	CcSEcCtD
Vismodegib—Arthralgia—Mycophenolate mofetil—psoriasis	8.51e-05	0.00164	CcSEcCtD
Vismodegib—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.5e-05	0.00292	CbGpPWpGaD
Vismodegib—Breast disorder—Methotrexate—psoriasis	8.5e-05	0.00163	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mycophenolic acid—psoriasis	8.45e-05	0.00162	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	8.45e-05	0.00162	CcSEcCtD
Vismodegib—Diarrhoea—Hydroxyurea—psoriasis	8.44e-05	0.00162	CcSEcCtD
Vismodegib—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	8.41e-05	0.00289	CbGpPWpGaD
Vismodegib—Dysgeusia—Triamcinolone—psoriasis	8.4e-05	0.00161	CcSEcCtD
Vismodegib—Back pain—Triamcinolone—psoriasis	8.29e-05	0.00159	CcSEcCtD
Vismodegib—Nervous system disorder—Cyclosporine—psoriasis	8.2e-05	0.00158	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	8.19e-05	0.00281	CbGpPWpGaD
Vismodegib—Abdominal pain—Mycophenolic acid—psoriasis	8.17e-05	0.00157	CcSEcCtD
Vismodegib—Skin disorder—Cyclosporine—psoriasis	8.12e-05	0.00156	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—CCL20—psoriasis	8.03e-05	0.00276	CbGpPWpGaD
Vismodegib—ALB—Lipoprotein metabolism—APOE—psoriasis	8e-05	0.00275	CbGpPWpGaD
Vismodegib—Nervous system disorder—Mycophenolate mofetil—psoriasis	8e-05	0.00154	CcSEcCtD
Vismodegib—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.93e-05	0.00272	CbGpPWpGaD
Vismodegib—Skin disorder—Mycophenolate mofetil—psoriasis	7.92e-05	0.00152	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—TAGAP—psoriasis	7.92e-05	0.00272	CbGpPWpGaD
Vismodegib—Alopecia—Betamethasone—psoriasis	7.9e-05	0.00152	CcSEcCtD
Vismodegib—Alopecia—Dexamethasone—psoriasis	7.9e-05	0.00152	CcSEcCtD
Vismodegib—Vomiting—Hydroxyurea—psoriasis	7.85e-05	0.00151	CcSEcCtD
Vismodegib—Rash—Hydroxyurea—psoriasis	7.78e-05	0.0015	CcSEcCtD
Vismodegib—Dermatitis—Hydroxyurea—psoriasis	7.77e-05	0.00149	CcSEcCtD
Vismodegib—Myalgia—Hydrocortisone—psoriasis	7.75e-05	0.00149	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	7.7e-05	0.00148	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.66e-05	0.00263	CbGpPWpGaD
Vismodegib—Connective tissue disorder—Prednisone—psoriasis	7.65e-05	0.00147	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Cyclosporine—psoriasis	7.62e-05	0.00146	CcSEcCtD
Vismodegib—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.61e-05	0.00262	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL20—psoriasis	7.61e-05	0.00262	CbGpPWpGaD
Vismodegib—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	7.51e-05	0.00258	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TAGAP—psoriasis	7.51e-05	0.00258	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	7.43e-05	0.00143	CcSEcCtD
Vismodegib—Asthenia—Mycophenolic acid—psoriasis	7.42e-05	0.00143	CcSEcCtD
Vismodegib—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.4e-05	0.00255	CbGpPWpGaD
Vismodegib—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	7.38e-05	0.00254	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	7.37e-05	0.00253	CbGpPWpGaD
Vismodegib—Dyspepsia—Cyclosporine—psoriasis	7.36e-05	0.00141	CcSEcCtD
Vismodegib—Nausea—Hydroxyurea—psoriasis	7.33e-05	0.00141	CcSEcCtD
Vismodegib—Pruritus—Mycophenolic acid—psoriasis	7.31e-05	0.00141	CcSEcCtD
Vismodegib—Myalgia—Triamcinolone—psoriasis	7.3e-05	0.0014	CcSEcCtD
Vismodegib—Nervous system disorder—Hydrocortisone—psoriasis	7.29e-05	0.0014	CcSEcCtD
Vismodegib—Decreased appetite—Cyclosporine—psoriasis	7.27e-05	0.0014	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.26e-05	0.0025	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Cyclosporine—psoriasis	7.22e-05	0.00139	CcSEcCtD
Vismodegib—Skin disorder—Hydrocortisone—psoriasis	7.22e-05	0.00139	CcSEcCtD
Vismodegib—Fatigue—Cyclosporine—psoriasis	7.21e-05	0.00139	CcSEcCtD
Vismodegib—Dyspepsia—Mycophenolate mofetil—psoriasis	7.18e-05	0.00138	CcSEcCtD
Vismodegib—Pain—Cyclosporine—psoriasis	7.15e-05	0.00137	CcSEcCtD
Vismodegib—Constipation—Cyclosporine—psoriasis	7.15e-05	0.00137	CcSEcCtD
Vismodegib—Decreased appetite—Mycophenolate mofetil—psoriasis	7.09e-05	0.00136	CcSEcCtD
Vismodegib—Diarrhoea—Mycophenolic acid—psoriasis	7.07e-05	0.00136	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	7.04e-05	0.00135	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.99e-05	0.0024	CbGpPWpGaD
Vismodegib—Pain—Mycophenolate mofetil—psoriasis	6.98e-05	0.00134	CcSEcCtD
Vismodegib—Constipation—Mycophenolate mofetil—psoriasis	6.98e-05	0.00134	CcSEcCtD
Vismodegib—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.94e-05	0.00239	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	6.9e-05	0.00237	CbGpPWpGaD
Vismodegib—Alopecia—Prednisone—psoriasis	6.88e-05	0.00132	CcSEcCtD
Vismodegib—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.85e-05	0.00235	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Cyclosporine—psoriasis	6.84e-05	0.00131	CcSEcCtD
Vismodegib—Malnutrition—Prednisone—psoriasis	6.77e-05	0.0013	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.77e-05	0.0013	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.69e-05	0.0023	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.67e-05	0.00128	CcSEcCtD
Vismodegib—Myalgia—Betamethasone—psoriasis	6.62e-05	0.00127	CcSEcCtD
Vismodegib—Myalgia—Dexamethasone—psoriasis	6.62e-05	0.00127	CcSEcCtD
Vismodegib—Abdominal pain—Cyclosporine—psoriasis	6.61e-05	0.00127	CcSEcCtD
Vismodegib—Vomiting—Mycophenolic acid—psoriasis	6.57e-05	0.00126	CcSEcCtD
Vismodegib—Dyspepsia—Hydrocortisone—psoriasis	6.54e-05	0.00126	CcSEcCtD
Vismodegib—ALB—Hemostasis—SERPINB8—psoriasis	6.53e-05	0.00224	CbGpPWpGaD
Vismodegib—Rash—Mycophenolic acid—psoriasis	6.52e-05	0.00125	CcSEcCtD
Vismodegib—Dermatitis—Mycophenolic acid—psoriasis	6.51e-05	0.00125	CcSEcCtD
Vismodegib—Pain—Prednisolone—psoriasis	6.51e-05	0.00125	CcSEcCtD
Vismodegib—Decreased appetite—Hydrocortisone—psoriasis	6.46e-05	0.00124	CcSEcCtD
Vismodegib—Abdominal pain—Mycophenolate mofetil—psoriasis	6.45e-05	0.00124	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.43e-05	0.00221	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Hydrocortisone—psoriasis	6.42e-05	0.00123	CcSEcCtD
Vismodegib—Fatigue—Hydrocortisone—psoriasis	6.41e-05	0.00123	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Triamcinolone—psoriasis	6.37e-05	0.00123	CcSEcCtD
Vismodegib—Pain—Hydrocortisone—psoriasis	6.35e-05	0.00122	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.34e-05	0.00218	CbGpPWpGaD
Vismodegib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	6.33e-05	0.00218	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-C—psoriasis	6.32e-05	0.00217	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL13—psoriasis	6.28e-05	0.00216	CbGpPWpGaD
Vismodegib—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	6.23e-05	0.00214	CbGpPWpGaD
Vismodegib—Nervous system disorder—Dexamethasone—psoriasis	6.23e-05	0.0012	CcSEcCtD
Vismodegib—Nervous system disorder—Betamethasone—psoriasis	6.23e-05	0.0012	CcSEcCtD
Vismodegib—Dyspepsia—Triamcinolone—psoriasis	6.16e-05	0.00118	CcSEcCtD
Vismodegib—Nausea—Mycophenolic acid—psoriasis	6.14e-05	0.00118	CcSEcCtD
Vismodegib—Gastrointestinal pain—Hydrocortisone—psoriasis	6.08e-05	0.00117	CcSEcCtD
Vismodegib—Fatigue—Triamcinolone—psoriasis	6.03e-05	0.00116	CcSEcCtD
Vismodegib—Asthenia—Cyclosporine—psoriasis	6e-05	0.00115	CcSEcCtD
Vismodegib—Pain—Triamcinolone—psoriasis	5.98e-05	0.00115	CcSEcCtD
Vismodegib—Pruritus—Cyclosporine—psoriasis	5.92e-05	0.00114	CcSEcCtD
Vismodegib—Abdominal pain—Hydrocortisone—psoriasis	5.87e-05	0.00113	CcSEcCtD
Vismodegib—Asthenia—Mycophenolate mofetil—psoriasis	5.85e-05	0.00112	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.78e-05	0.00111	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Betamethasone—psoriasis	5.78e-05	0.00111	CcSEcCtD
Vismodegib—ABCB1—Allograft Rejection—IL17A—psoriasis	5.78e-05	0.00199	CbGpPWpGaD
Vismodegib—Pruritus—Mycophenolate mofetil—psoriasis	5.77e-05	0.00111	CcSEcCtD
Vismodegib—Arthralgia—Prednisone—psoriasis	5.77e-05	0.00111	CcSEcCtD
Vismodegib—Myalgia—Prednisone—psoriasis	5.77e-05	0.00111	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—psoriasis	5.75e-05	0.0011	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.73e-05	0.00197	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.73e-05	0.0011	CcSEcCtD
Vismodegib—Diarrhoea—Cyclosporine—psoriasis	5.72e-05	0.0011	CcSEcCtD
Vismodegib—Malnutrition—Methotrexate—psoriasis	5.66e-05	0.00109	CcSEcCtD
Vismodegib—Dyspepsia—Betamethasone—psoriasis	5.59e-05	0.00107	CcSEcCtD
Vismodegib—Dyspepsia—Dexamethasone—psoriasis	5.59e-05	0.00107	CcSEcCtD
Vismodegib—Diarrhoea—Mycophenolate mofetil—psoriasis	5.58e-05	0.00107	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—psoriasis	5.54e-05	0.00107	CcSEcCtD
Vismodegib—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.53e-05	0.0019	CbGpPWpGaD
Vismodegib—Decreased appetite—Dexamethasone—psoriasis	5.52e-05	0.00106	CcSEcCtD
Vismodegib—Decreased appetite—Betamethasone—psoriasis	5.52e-05	0.00106	CcSEcCtD
Vismodegib—ALB—Folate Metabolism—CAT—psoriasis	5.48e-05	0.00188	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Dexamethasone—psoriasis	5.48e-05	0.00105	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Betamethasone—psoriasis	5.48e-05	0.00105	CcSEcCtD
Vismodegib—Back pain—Methotrexate—psoriasis	5.48e-05	0.00105	CcSEcCtD
Vismodegib—Fatigue—Betamethasone—psoriasis	5.47e-05	0.00105	CcSEcCtD
Vismodegib—Fatigue—Dexamethasone—psoriasis	5.47e-05	0.00105	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.44e-05	0.00187	CbGpPWpGaD
Vismodegib—Pain—Betamethasone—psoriasis	5.43e-05	0.00104	CcSEcCtD
Vismodegib—Pain—Dexamethasone—psoriasis	5.43e-05	0.00104	CcSEcCtD
Vismodegib—Nervous system disorder—Prednisone—psoriasis	5.42e-05	0.00104	CcSEcCtD
Vismodegib—ABCB1—Allograft Rejection—IL12B—psoriasis	5.37e-05	0.00185	CbGpPWpGaD
Vismodegib—Skin disorder—Prednisone—psoriasis	5.37e-05	0.00103	CcSEcCtD
Vismodegib—ALB—Vitamin B12 Metabolism—CRP—psoriasis	5.35e-05	0.00184	CbGpPWpGaD
Vismodegib—Asthenia—Hydrocortisone—psoriasis	5.33e-05	0.00102	CcSEcCtD
Vismodegib—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	5.32e-05	0.00183	CbGpPWpGaD
Vismodegib—Vomiting—Cyclosporine—psoriasis	5.32e-05	0.00102	CcSEcCtD
Vismodegib—Rash—Cyclosporine—psoriasis	5.27e-05	0.00101	CcSEcCtD
Vismodegib—Dermatitis—Cyclosporine—psoriasis	5.27e-05	0.00101	CcSEcCtD
Vismodegib—Pruritus—Hydrocortisone—psoriasis	5.26e-05	0.00101	CcSEcCtD
Vismodegib—ABCB1—Allograft Rejection—HLA-E—psoriasis	5.24e-05	0.0018	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—APOE—psoriasis	5.23e-05	0.0018	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Betamethasone—psoriasis	5.19e-05	0.000998	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dexamethasone—psoriasis	5.19e-05	0.000998	CcSEcCtD
Vismodegib—Vomiting—Mycophenolate mofetil—psoriasis	5.19e-05	0.000997	CcSEcCtD
Vismodegib—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.16e-05	0.00177	CbGpPWpGaD
Vismodegib—Rash—Mycophenolate mofetil—psoriasis	5.14e-05	0.000989	CcSEcCtD
Vismodegib—Dermatitis—Mycophenolate mofetil—psoriasis	5.14e-05	0.000988	CcSEcCtD
Vismodegib—Diarrhoea—Hydrocortisone—psoriasis	5.08e-05	0.000977	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.05e-05	0.00174	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Prednisone—psoriasis	5.04e-05	0.000968	CcSEcCtD
Vismodegib—ALB—Folate Metabolism—IL4—psoriasis	5.04e-05	0.00173	CbGpPWpGaD
Vismodegib—Asthenia—Triamcinolone—psoriasis	5.02e-05	0.000965	CcSEcCtD
Vismodegib—Abdominal pain—Betamethasone—psoriasis	5.02e-05	0.000965	CcSEcCtD
Vismodegib—Abdominal pain—Dexamethasone—psoriasis	5.02e-05	0.000965	CcSEcCtD
Vismodegib—Nausea—Cyclosporine—psoriasis	4.97e-05	0.000955	CcSEcCtD
Vismodegib—Pruritus—Triamcinolone—psoriasis	4.95e-05	0.000952	CcSEcCtD
Vismodegib—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	4.92e-05	0.00169	CbGpPWpGaD
Vismodegib—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	4.9e-05	0.00168	CbGpPWpGaD
Vismodegib—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.88e-05	0.00168	CbGpPWpGaD
Vismodegib—Dyspepsia—Prednisone—psoriasis	4.87e-05	0.000936	CcSEcCtD
Vismodegib—Nausea—Mycophenolate mofetil—psoriasis	4.84e-05	0.000931	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—psoriasis	4.82e-05	0.000927	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—psoriasis	4.82e-05	0.000927	CcSEcCtD
Vismodegib—Decreased appetite—Prednisone—psoriasis	4.81e-05	0.000924	CcSEcCtD
Vismodegib—Rash—Prednisolone—psoriasis	4.8e-05	0.000922	CcSEcCtD
Vismodegib—Dermatitis—Prednisolone—psoriasis	4.79e-05	0.000921	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.79e-05	0.00165	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.79e-05	0.00092	CcSEcCtD
Vismodegib—Fatigue—Prednisone—psoriasis	4.77e-05	0.000916	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—CCL20—psoriasis	4.74e-05	0.00163	CbGpPWpGaD
Vismodegib—Constipation—Prednisone—psoriasis	4.73e-05	0.000909	CcSEcCtD
Vismodegib—Vomiting—Hydrocortisone—psoriasis	4.72e-05	0.000908	CcSEcCtD
Vismodegib—Rash—Hydrocortisone—psoriasis	4.69e-05	0.000901	CcSEcCtD
Vismodegib—Dermatitis—Hydrocortisone—psoriasis	4.68e-05	0.0009	CcSEcCtD
Vismodegib—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.58e-05	0.00157	CbGpPWpGaD
Vismodegib—Asthenia—Dexamethasone—psoriasis	4.56e-05	0.000876	CcSEcCtD
Vismodegib—Asthenia—Betamethasone—psoriasis	4.56e-05	0.000876	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—psoriasis	4.53e-05	0.000871	CcSEcCtD
Vismodegib—Gastrointestinal pain—Prednisone—psoriasis	4.52e-05	0.000869	CcSEcCtD
Vismodegib—Nausea—Prednisolone—psoriasis	4.52e-05	0.000869	CcSEcCtD
Vismodegib—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.52e-05	0.00155	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL20—psoriasis	4.5e-05	0.00155	CbGpPWpGaD
Vismodegib—Pruritus—Dexamethasone—psoriasis	4.49e-05	0.000863	CcSEcCtD
Vismodegib—Pruritus—Betamethasone—psoriasis	4.49e-05	0.000863	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—psoriasis	4.49e-05	0.000863	CcSEcCtD
Vismodegib—Vomiting—Triamcinolone—psoriasis	4.45e-05	0.000855	CcSEcCtD
Vismodegib—Nausea—Hydrocortisone—psoriasis	4.41e-05	0.000848	CcSEcCtD
Vismodegib—Rash—Triamcinolone—psoriasis	4.41e-05	0.000848	CcSEcCtD
Vismodegib—Dermatitis—Triamcinolone—psoriasis	4.41e-05	0.000847	CcSEcCtD
Vismodegib—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.39e-05	0.00151	CbGpPWpGaD
Vismodegib—Abdominal pain—Prednisone—psoriasis	4.37e-05	0.00084	CcSEcCtD
Vismodegib—ALB—Selenium Micronutrient Network—CAT—psoriasis	4.35e-05	0.0015	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—CRP—psoriasis	4.35e-05	0.0015	CbGpPWpGaD
Vismodegib—Diarrhoea—Dexamethasone—psoriasis	4.34e-05	0.000835	CcSEcCtD
Vismodegib—Diarrhoea—Betamethasone—psoriasis	4.34e-05	0.000835	CcSEcCtD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.34e-05	0.00149	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	4.26e-05	0.00147	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CXCL8—psoriasis	4.23e-05	0.00145	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Methotrexate—psoriasis	4.21e-05	0.000809	CcSEcCtD
Vismodegib—Nausea—Triamcinolone—psoriasis	4.16e-05	0.000799	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—psoriasis	4.07e-05	0.000782	CcSEcCtD
Vismodegib—Vomiting—Dexamethasone—psoriasis	4.04e-05	0.000776	CcSEcCtD
Vismodegib—Vomiting—Betamethasone—psoriasis	4.04e-05	0.000776	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—psoriasis	4.02e-05	0.000772	CcSEcCtD
Vismodegib—SMO—GPCR ligand binding—CXCL8—psoriasis	4.01e-05	0.00138	CbGpPWpGaD
Vismodegib—Rash—Dexamethasone—psoriasis	4e-05	0.000769	CcSEcCtD
Vismodegib—Rash—Betamethasone—psoriasis	4e-05	0.000769	CcSEcCtD
Vismodegib—ALB—Folate Metabolism—ICAM1—psoriasis	4e-05	0.00138	CbGpPWpGaD
Vismodegib—Dermatitis—Betamethasone—psoriasis	4e-05	0.000769	CcSEcCtD
Vismodegib—Dermatitis—Dexamethasone—psoriasis	4e-05	0.000769	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—psoriasis	3.99e-05	0.000767	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—psoriasis	3.98e-05	0.000766	CcSEcCtD
Vismodegib—Asthenia—Prednisone—psoriasis	3.97e-05	0.000763	CcSEcCtD
Vismodegib—Pain—Methotrexate—psoriasis	3.95e-05	0.00076	CcSEcCtD
Vismodegib—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.95e-05	0.00136	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL10—psoriasis	3.93e-05	0.00135	CbGpPWpGaD
Vismodegib—Pruritus—Prednisone—psoriasis	3.91e-05	0.000752	CcSEcCtD
Vismodegib—ABCB1—Allograft Rejection—IL4—psoriasis	3.82e-05	0.00131	CbGpPWpGaD
Vismodegib—Diarrhoea—Prednisone—psoriasis	3.78e-05	0.000727	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—psoriasis	3.78e-05	0.000726	CcSEcCtD
Vismodegib—Nausea—Dexamethasone—psoriasis	3.77e-05	0.000725	CcSEcCtD
Vismodegib—Nausea—Betamethasone—psoriasis	3.77e-05	0.000725	CcSEcCtD
Vismodegib—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	3.74e-05	0.00129	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.74e-05	0.00128	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.73e-05	0.00128	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.73e-05	0.00128	CbGpPWpGaD
Vismodegib—Abdominal pain—Methotrexate—psoriasis	3.65e-05	0.000702	CcSEcCtD
Vismodegib—Vomiting—Prednisone—psoriasis	3.52e-05	0.000676	CcSEcCtD
Vismodegib—Rash—Prednisone—psoriasis	3.49e-05	0.00067	CcSEcCtD
Vismodegib—Dermatitis—Prednisone—psoriasis	3.48e-05	0.000669	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.48e-05	0.0012	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.46e-05	0.00119	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—CRP—psoriasis	3.46e-05	0.00119	CbGpPWpGaD
Vismodegib—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.4e-05	0.00117	CbGpPWpGaD
Vismodegib—Asthenia—Methotrexate—psoriasis	3.32e-05	0.000637	CcSEcCtD
Vismodegib—Nausea—Prednisone—psoriasis	3.28e-05	0.000631	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—psoriasis	3.27e-05	0.000628	CcSEcCtD
Vismodegib—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.18e-05	0.00109	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.16e-05	0.00109	CbGpPWpGaD
Vismodegib—Diarrhoea—Methotrexate—psoriasis	3.16e-05	0.000608	CcSEcCtD
Vismodegib—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.12e-05	0.00107	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.11e-05	0.00107	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IFNG—psoriasis	3.04e-05	0.00105	CbGpPWpGaD
Vismodegib—SHH—Disease—HLA-A—psoriasis	2.95e-05	0.00101	CbGpPWpGaD
Vismodegib—Vomiting—Methotrexate—psoriasis	2.94e-05	0.000565	CcSEcCtD
Vismodegib—Rash—Methotrexate—psoriasis	2.91e-05	0.00056	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—psoriasis	2.91e-05	0.00056	CcSEcCtD
Vismodegib—ABCG2—Metabolism—NDUFA5—psoriasis	2.76e-05	0.00095	CbGpPWpGaD
Vismodegib—SHH—Disease—APOE—psoriasis	2.75e-05	0.000946	CbGpPWpGaD
Vismodegib—Nausea—Methotrexate—psoriasis	2.74e-05	0.000528	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—SOCS1—psoriasis	2.61e-05	0.000898	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.57e-05	0.000883	CbGpPWpGaD
Vismodegib—SHH—Disease—NOS2—psoriasis	2.56e-05	0.000882	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—NFKB1—psoriasis	2.53e-05	0.000871	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—TYK2—psoriasis	2.49e-05	0.000856	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SOCS1—psoriasis	2.48e-05	0.000851	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.45e-05	0.000842	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.42e-05	0.000832	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.42e-05	0.000831	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—TYK2—psoriasis	2.36e-05	0.000811	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000808	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IFNG—psoriasis	2.31e-05	0.000794	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.31e-05	0.000792	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CXCL8—psoriasis	2.17e-05	0.000745	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.15e-05	0.000738	CbGpPWpGaD
Vismodegib—SHH—Disease—TYK2—psoriasis	2.1e-05	0.000722	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CXCL8—psoriasis	2.06e-05	0.000707	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.01e-05	0.000692	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.01e-05	0.000692	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—VEGFA—psoriasis	1.97e-05	0.000677	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TNF—psoriasis	1.97e-05	0.000677	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.95e-05	0.000672	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—APOE—psoriasis	1.93e-05	0.000663	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—LEP—psoriasis	1.93e-05	0.000663	CbGpPWpGaD
Vismodegib—SHH—Disease—CD4—psoriasis	1.9e-05	0.000653	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—ITGAL—psoriasis	1.9e-05	0.000652	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.88e-05	0.000645	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—LEP—psoriasis	1.83e-05	0.000628	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—APOE—psoriasis	1.83e-05	0.000628	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NFKBIA—psoriasis	1.8e-05	0.000617	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.77e-05	0.000608	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.74e-05	0.0006	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—psoriasis	1.74e-05	0.000597	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NDUFA5—psoriasis	1.72e-05	0.00059	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NDUFA5—psoriasis	1.71e-05	0.000586	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NFKBIA—psoriasis	1.7e-05	0.000585	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.6e-05	0.00055	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.59e-05	0.000547	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL6—psoriasis	1.59e-05	0.000546	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.59e-05	0.000545	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.57e-05	0.000538	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NDUFA5—psoriasis	1.53e-05	0.000526	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.51e-05	0.00052	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—TNF—psoriasis	1.49e-05	0.000514	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NDUFA5—psoriasis	1.49e-05	0.000514	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.49e-05	0.000511	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TYK2—psoriasis	1.47e-05	0.000506	CbGpPWpGaD
Vismodegib—SHH—Disease—STAT3—psoriasis	1.47e-05	0.000506	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP2S1—psoriasis	1.46e-05	0.000501	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP2S1—psoriasis	1.45e-05	0.000499	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.43e-05	0.000491	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NDUFA5—psoriasis	1.4e-05	0.00048	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TYK2—psoriasis	1.39e-05	0.000479	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.39e-05	0.000477	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.33e-05	0.000455	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP2S1—psoriasis	1.3e-05	0.000448	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.3e-05	0.000447	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCL8—psoriasis	1.28e-05	0.00044	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP2S1—psoriasis	1.27e-05	0.000437	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.26e-05	0.000434	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—IL6—psoriasis	1.22e-05	0.000419	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL8—psoriasis	1.21e-05	0.000417	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—JUN—psoriasis	1.19e-05	0.000409	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP2S1—psoriasis	1.19e-05	0.000408	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—IL6—psoriasis	1.15e-05	0.000397	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CARM1—psoriasis	1.15e-05	0.000395	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NFKB1—psoriasis	1.15e-05	0.000394	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—JUN—psoriasis	1.13e-05	0.000388	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NFKB1—psoriasis	1.09e-05	0.000373	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—psoriasis	1.04e-05	0.000358	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—STAT3—psoriasis	1.03e-05	0.000354	CbGpPWpGaD
Vismodegib—SHH—Disease—IL6—psoriasis	1.03e-05	0.000353	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—psoriasis	9.86e-06	0.000339	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.85e-06	0.000339	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—STAT3—psoriasis	9.76e-06	0.000336	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	9.48e-06	0.000326	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NDUFA5—psoriasis	9.21e-06	0.000317	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	8.74e-06	0.0003	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.61e-06	0.000296	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—psoriasis	7.86e-06	0.00027	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP2S1—psoriasis	7.83e-06	0.000269	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NOS2—psoriasis	7.78e-06	0.000267	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.64e-06	0.000263	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.6e-06	0.000261	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—psoriasis	7.45e-06	0.000256	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.38e-06	0.000254	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—IL6—psoriasis	7.19e-06	0.000247	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CARM1—psoriasis	7.12e-06	0.000245	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CARM1—psoriasis	7.08e-06	0.000243	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CAT—psoriasis	7.06e-06	0.000243	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.82e-06	0.000235	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IL6—psoriasis	6.82e-06	0.000234	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.66e-06	0.000229	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.62e-06	0.000228	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.5e-06	0.000224	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CARM1—psoriasis	6.36e-06	0.000219	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.22e-06	0.000214	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CARM1—psoriasis	6.21e-06	0.000213	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.94e-06	0.000204	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CARM1—psoriasis	5.8e-06	0.000199	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—APOE—psoriasis	5.49e-06	0.000189	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.42e-06	0.000186	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPARG—psoriasis	4.78e-06	0.000164	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—psoriasis	4.51e-06	0.000155	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CAT—psoriasis	4.38e-06	0.000151	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CAT—psoriasis	4.36e-06	0.00015	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CAT—psoriasis	3.91e-06	0.000134	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CARM1—psoriasis	3.82e-06	0.000131	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CAT—psoriasis	3.82e-06	0.000131	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CAT—psoriasis	3.57e-06	0.000123	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—psoriasis	3.4e-06	0.000117	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—APOE—psoriasis	3.4e-06	0.000117	CbGpPWpGaD
Vismodegib—ALB—Metabolism—APOE—psoriasis	3.39e-06	0.000116	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—APOE—psoriasis	3.04e-06	0.000104	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—APOE—psoriasis	2.97e-06	0.000102	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARG—psoriasis	2.97e-06	0.000102	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARG—psoriasis	2.95e-06	0.000101	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—APOE—psoriasis	2.77e-06	9.52e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARG—psoriasis	2.65e-06	9.1e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARG—psoriasis	2.58e-06	8.88e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARG—psoriasis	2.41e-06	8.3e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CAT—psoriasis	2.35e-06	8.08e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—APOE—psoriasis	1.83e-06	6.28e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARG—psoriasis	1.59e-06	5.47e-05	CbGpPWpGaD
